#dyne251
LightNews LightNews
rarediseaseadvisor.bsky.social
#DYNE251, an investigational exon 51-skipping therapy, provides sustained improvements in muscle function and potentially preserves #Cardiopulmonary function in patients with #DMD. Data to be presented at the 2026 @mda.org #MDAConference

Learn more: https://bit.ly/46C0ZyI

#RareDisease #MedSky
Z-Rostudirsen for DMD May Improve Muscle Function, With Signals of Cardiopulmonary Benefit
Data from the DELIVER trial of z-rostudirsen in DMD showed sustained improvement in muscle function and potential cardiopulmonary benefit.
bit.ly
March 5, 2026 at 8:53 PM
dmdwarrior.com
Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #dyne #dyne251 #dyne101
Plans for DYNE-101 in DM1 and DYNE-251 in DMD Are Announced by Dyne Therapeutics Dyne Therapeutics announces clinical trial plans for DYNE-101 and DYNE-251, targeting myotonic dystrophy and Duchenne muscular dystrophy. Dyne Therapeutics announced positive clinical data for its therapies DYNE-101 and DYNE-251 during an investor event on January 10, 2025. DYNE-101 for myotonic dystrophy type 1 (DM1) demonstrated significant splicing correction and functional improvements, leading Dyne to plan a global Registrational Expansion Cohort of the ACHIEVE trial with a registrational dose of 6.8 mg/kg Q8W and a potential U.S. Accelerated Approval submission in H1 2026. Meanwhile, DYNE-251, targeting Duchenne muscular dystrophy (DMD), is also pursuing U.S. Accelerated Approval based on dystrophin as a surrogate endpoint, with data expected by late 2025 to support an early 2026 submission. Both programs show promise in transforming treatment paradigms for these genetic diseases.
January 10, 2025 at 2:07 PM
theakarifoundation.bsky.social
🔗Lee el artículo completo en el siguiente link: https://theakarifoundation.org/blog

Da clic en el link de nuestro perfil y visita nuestros ARTÍCULOS más recientes.

#enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #DyneTherapeutics #DYNE251 #zrostudirsen #AkariJulio
July 20, 2026 at 7:36 PM